Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | HRH1 | P35367 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Didesmethylimipramine SCHEMBL10376169 | 0.88 | HTR2A (1.00) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL9689277 | 0.87 | HTR2A (0.62) | HTR2ACHRM2CHRM1ADRA1ADRD3 | |
| Didesmethylimipramine SCHEMBL11388787 | 0.86 | HTR2A (0.96) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL17390908 | 0.86 | HTR2A (0.89) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL4669145 | 0.85 | CYP3A4 (0.65) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL21245974 | 0.85 | HTR2A (0.86) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| Hydrochloric Acid SCHEMBL14698925 | 0.84 | MEN1 (0.66) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL13051501 | 0.83 | HTR2A (0.78) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL1798507 | 0.79 | HTR2A (0.81) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 | |
| SCHEMBL9404599 | 0.79 | HTR2A (0.61) | HTR2ASLC6A4SLC6A2CYP3A4SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-0226730-B1 | Compounds and assay for tricyclic antidepressants | ABBOTT LAB (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0226730-A2 | Compounds and assay for tricyclic antidepressants | ABBOTT LABORATORIES (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | HTR2A 1763/4885SLC6A4 167/4885SLC6A2 1127/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | HTR2A 1763/4885SLC6A4 167/4885SLC6A2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.